copper dotatate Cu-64 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
5411 1426155-87-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • copper dotatate Cu-64
  • copper dotatate Cu64
  • copper dotatate
  • detectnet
Copper Cu-64 dotatate is a radioactive diagnostic drug. It binds to somatostatin receptors with highest affinity for subtype 2 receptors (SSTR2). It binds to cells that express somatostatin receptors including malignant neuroendocrine cells, which overexpress SSTR2 receptors. Copper Cu 64 is a positron (beta+) emitting radionuclide with an emission yield that allows positron emission tomography (PET) imaging.
  • Molecular weight: 1497.55
  • Formula: C65H88CuN14O19S2
  • CLOGP: -9.02
  • LIPINSKI: 3
  • HAC: 33
  • HDO: 15
  • TPSA: 462.50
  • ALOGS: -4.18
  • ROTB: 26

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Sept. 3, 2020 FDA RADIOMEDIX

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

None

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Positron emission tomography indication 82918005




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
4mL (1mCi/ML) DETECTNET RADIOMEDIX N213227 Sept. 3, 2020 RX SOLUTION INTRAVENOUS 10159759 Aug. 23, 2032 USE OF CU-64 DOTATATE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT PATIENTS
4mL (1mCi/ML) DETECTNET RADIOMEDIX N213227 Sept. 3, 2020 RX SOLUTION INTRAVENOUS 10383961 Aug. 23, 2032 USE OF CU-64 DOTATATE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT PATIENTS
4mL (1mCi/ML) DETECTNET RADIOMEDIX N213227 Sept. 3, 2020 RX SOLUTION INTRAVENOUS 11160888 Aug. 23, 2032 USE OF CU-64 DOTATATE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT PATIENTS

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
4mL (1mCi/ML) DETECTNET RADIOMEDIX N213227 Sept. 3, 2020 RX SOLUTION INTRAVENOUS Sept. 3, 2025 NEW CHEMICAL ENTITY
4mL (1mCi/ML) DETECTNET RADIOMEDIX N213227 Sept. 3, 2020 RX SOLUTION INTRAVENOUS Sept. 3, 2027 FOR USE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT PATIENTS

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Somatostatin receptor type 2 GPCR BINDING AGENT Kd 7.69 SCIENTIFIC LITERATURE DRUG LABEL

External reference:

IDSource
D11882 KEGG_DRUG
CHEMBL4297339 ChEMBL_ID
C000718307 MESH_SUPPLEMENTAL_RECORD_UI
124220636 PUBCHEM_CID
DB15873 DRUGBANK_ID
2396442 RXNORM
340817 MMSL
d09680 MMSL
926371003 SNOMEDCT_US
926394002 SNOMEDCT_US
C3502191 UMLSCUI
N3858377KC UNII

Pharmaceutical products:

None